ECOR — Electrocore LLC
NASDAQ · Healthcare · Medical Devices
$9.31
+$0.26 (+2.93%)
Electrocore LLC (ECOR) is a medical devices company listed on NASDAQ. It is led by Daniel S. Goldberger, based in 200 Forge Way, Rockaway, NJ, United States, 07866, with about 73 employees. electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation ("nVNS") technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Latest reported ECOR revenue for 2025-09-30 was $8.7M. Net income was -$3.4M. Revenue was up 17.7% from 2025-06-30 to 2025-09-30. ECOR currently screens at market cap $45.3M.
Use this ECOR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ECOR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ECOR SEC filings page. Lician reads the product cache first so this HTML stays unique to Electrocore LLC even when a live quote feed is slow.
About Electrocore LLC
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation ("nVNS") technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
ECOR Key Statistics
Market Cap
$45.34M
Volume
77,982
Previous Close
$9.47
Day Range
$9.45 – $10.35
EPS
-$1.59
Revenue
$25.18M
Net Income
-$11.89M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+57.1%
Profit Margin
-47.2%
Employees
73
ECOR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $25.18M | $16.03M | $8.59M | $5.45M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$11.89M | -$18.83M | -$22.16M | -$17.22M |
| EPS (Diluted) | -$1.59 | -$3.42 | -$4.69 | -$4.36 |
Total Assets
$20.47M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.45M
Operating Cash Flow
-$6.95M
Free Cash Flow
$0.00
Electrocore LLC Company Information
- CEO & Director
- Daniel S. Goldberger
- Headquarters
- 200 Forge Way, Rockaway, NJ, United States, 07866
- Website
- www.electrocore.com
- Phone
- 973 290 0097
- IPO / Founded
- 2018-06-22
- Sector
- Healthcare
- Industry
- Medical Devices